OUTCOMES OF TUBERCULOSIS TREATMENT DEPENDING ON CYP2C19 GENOTYPE

P.B. Antonenko, V.I. Kresyun

Odessa National Medical University

Key words: tuberculosis; CYP2C19; treatment outcome

As proven earlier, in patients with tuberculosis (TB) the concentration of antituberculous drugs like isoniazid and rifampicin may differ depending on polymorphism of CYP2C19. The aim of the research was to determine the peculiarities of the pulmonary TB course and its outcome after the in-patient treatment depending on CYP2C19 genotype of the patients. The analysis of medical cards from 83 patients with the primary pulmonary tuberculosis at the end of the in-patient treatment in Odessa regional TB dispensary was conducted in 2012 with consideration of CYP2C19 genotype. At the beginning of the treatment the processes of disintegration were 3 times less in patients with *1/*1 genotype than in patients with *1/*2 genotype (10.3% versus 31.8%; P<0.05; χ²=5.40), and 6.5 times less than in individuals with *2/*2 genotype (10.3% versus 66.7%; P<0.05; χ²=7.94). At the end of the in-patient treatment the signs of pulmonary destruction were 6.5 times more common in individuals with *1/*1 genotype than in individuals with *1/*2 genotype (29.3 versus 4.5; P<0.05; χ²=5.61). The signs of resorption and consolidation in the pulmonary tissue were observed in 74.1% of the patients with *1/*1 genotype, 95.5% of the patients with *1/*2 genotype and 66.7% of the patients with *2/*2 genotype. There were no significant differences between groups in relation to duration of the treatment and development of drug-resistance.

Today, tuberculosis (TB) or “white plague” remains a major cause of death among infectious diseases in Ukraine. Despite certain positive changes, for example, reducing the TB incidence during the period of 2006-2011 from 83.2 to 67.2 per 100 000 of the population [5, 8], it is still a high level of multidrug-resistant tuberculosis – from 7 to 25% of the primary resistance to 75% of the secondary resistance, and it significantly reduces the efficiency of treatment [2, 7].

It is known that the efficiency of treatment of numerous diseases, the severity of their course and their outcome largely depend on the genetic characteristics of a person, for example from polymorphism of genes of xenobiotics detoxification [9, 11]. Among the last there is an important gene of cytochrome P<sub>450</sub> 2C19 (CYP2C19), the expression of which is activated by anti-TB antibiotic rifampicin [6]. On the other hand, rifampicin can be a substrate for CYP2C19 and polymorphism of its gene may affect the metabolism of rifampicin and consequently the efficiency of TB treatment. In previous studies it has been shown that TB patients have higher frequency of the variant alleles (*2, *3) than healthy people do, and it is also noted that polymorphism of CYP2C19 genotype in TB patients associated with differences of rifampicin and isoniazid concentrations [1, 2]. So, the next step was to study the efficiency of treatment of TB-patients considering CYP2C19 genotype.

The aim of the research is to detect the peculiarities of the pulmonary TB course and the outcome after the in-patient treatment depending on CYP2C19 genotype of the patients.

Materials and Methods

The analysis of medical cards from 83 patients with the primary pulmonary tuberculosis at the end of the in-patient treatment in Odessa regional TB dispensary was conducted in 2012. Among the enrolled patients 39 of them (47.0%) were women, others – 44 (53.0%) were men. The age varied from 18 to 73 years old (average – 35.9 years old). All TB patients received the same standard therapy according to the Order of Ministry of Public Health No. 384 from 9.06.2006 regardless of CYP2C19 genotype [4]. We considered medical diagnosis at the beginning and at the end of in-patients treatment, including TB-form, characteristics of TB-lesions, bacterial excretion, etc.

At the beginning of the treatment provided CYP2C19 genotype in TB-patients was detected. The DNA material was extracted from the blood of donors using a DNA sorbB kit (AmpliSens, Russian Federation). CYP2C19 genotype was detected with the help of the polymerase chain reaction (PCR) and endonuclease analysis according to J. A. Goldstein, J. Blaisdell, 2004 [10]. For PCR amplification of CYP2C19*2 and CYP2C19*3 alleles two pairs of relevant specific primers were used. PCR products of CYP2C19*2 and CYP2C19*3 were exposed to the action of restriction enzymes (restrictases) SmalI and BamHI, respectively. As the restriction was absent in the mutant alleles, PCR products avoided digestion by the corresponding restrictase enzymes. Processing of the statistical data obtained was performed using Microsoft Excel and “Primer Biostatistica” programmes.

Results and Discussion

In accordance with the genotype of CYP2C19 approximately 69.9% of TB-patients were carri-
ers of the homozygous wild type of the gene *1/*1, 26.5% – carriers of the heterozygous genotype *1/*2, and finally, 3.6% – carriers of the variant (mutated) genotype – *2/*2. For convenience it is possible to attribute the persons with *1/*1 genotype to rapid metabolizers (RM), persons with *1/*2 genotype to intermediate metabolizers (IM) and persons with *2/*2 genotype to slow metabolizers (SM).

At the beginning of the treatment in the in-patient department the destruction processes in lungs were observed approximately in one third of RM (37.9%), in half of IM and in all SM. Thus, one could see the processes of destruction in patients with *1/*1 genotype almost three times more often than in patients with *2/*2 genotype (P<0.05; \( \chi^2 = 4.54 \) at a critical value here and after 3.84) (Table 1).

Approximately one third of RM and IM had a bilateral pulmonary TB, about 66.7% of SM had a bilateral process as well. The disseminative pulmonary TB was observed almost in one third of genotype *1/*1 carriers (29.3%), in two-third of genotype *2/*2 carriers and only in 13.6% individuals with *1/*1 genotype.

In the majority of RM and IM an infiltrative TB was observed, in addition in IM it was 1.5 times more often than in RM (86.4% versus 58.6%, P<0.05; \( \chi^2 = 5.49 \)) (Fig. 1). A focal pulmonary TB was detected only in 12.1% of RM and it was completely absent in IM and SM.

Among the RM processes disintegration and dissemination in lungs occurred in 10.3 and 29.3%, respectively. (Table 1). At the same time among IM these processes were observed in 31.8% of the patients, among SM – in 66.7% and 33.3%, respectively. Thus, among the patients with *1/*1 genotype the processes of disintegration were 3 times less than in the patients with *1/*2 genotype (P<0.05; \( \chi^2 = 5.40 \)), and 6.5 times less than in individuals with *2/*2 genotype (P<0.05; \( \chi^2 = 7.94 \)). Meanwhile, the processes of the pulmonary tissues infiltration occurred more often in RM – 60.3%, almost twice as less in IM – 36.4% (P<0.05). On the contrary, the processes of infiltration were completely absent in SM (P<0.05; \( \chi^2 = 4.25 \)).

At the beginning of the in-patient treatment regardless of the genotype and according to the microscopy approximately half of the patients with genotype *1/*1 and *1/*2 (46.6% and 50.0%, respectively) and two-thirds of the individuals with genotype *2/*2 were smear-positive (Fig. 2). According to the cultural method the majority of patients – 62.5% of RM, 59.1% of IM and 66.7% of SM were smear-positive. The vast majority of the patients with the genotype of RM, IM or SM belonged to I (primary pulmonary tuberculosis) or III category (smear-negative primary tuberculosis) – 87.9%; 95.5% and 100% respectively. Thus, at the beginning of the treatment the patients with genotype *1/*1 had manifestations of disintegration and destruction in pulmonary tissues more often than carriers of *1/*2 or *2/*2 genotype.

Duration of the in-patient treatment was the longest in the individuals with *1/*1 genotype – 93.6±3.3 days. In the patients with *1/*2 or *2/*2 it was shorter – 86.8±2.7 days or 86.5±7.8 days, respectively.

### Table 1

**Characteristics of tuberculosis processes depending on CYP2C19 genotype**

| Characteristics of TB-processes | At the beginning of the treatment, (%) | At the end of the in-patient treatment, (%) |
|---------------------------------|---------------------------------------|---------------------------------------------|
|                                 | *1/*1, n=58                           | *1/*2, n=22                                 | *2/*2, n=3                                 |
| Spreading                       | 23 (39.7)                             | 7 (13.1)                                   | 2 (66.7)                                   |
|                                  | bilateral                             | unilateral                                 |                                            |
|                                  | 35 (60.3)                             | 15 (68.2)                                 | 1 (33.3)                                   |
| Destruction                      | yes                                   | 36 (62.1)                                 | 11 (50.0)                                 |
|                                  | no                                    |                                            | 3 (100)                                    |
|                                  | 17 (29.3)                             |                                            |                                            |
|                                  | 1*1#                                  |                                            |                                            |
|                                  | 1 (33.3)                              |                                            |                                            |
|                                  | 1 (33.3)                              |                                            |                                            |
| Stage of the TB-process          | infiltration                          | disintegration                             | dissemination                              |
|                                  | 35 (60.3)                             | 6 (10.3)                                  | 17 (29.3)                                 |
|                                  | 8 (36.4)                              | 7* (31.8)                                 | 7 (31.8)                                  |
|                                  | 0                                     | 2* (66.7)                                 | 1 (33.3)                                  |
|                                  | 41 (70.7)                             |                                            |                                            |
|                                  | 21 (95.5)                             |                                            |                                            |
|                                  | 2 (66.7)                              |                                            |                                            |
|                                  | 6*#                                   |                                            |                                            |
|                                  | 1 (4.5)                               |                                            |                                            |
|                                  | 1 (33.3)                              |                                            |                                            |
| Category of patients             | 1                                     | 2                                         | 3                                         | 4                                         |
|                                  | 39 (67.2)                             | 6 (10.3)                                  | 12 (20.7)                                 | 1 (1.7)                                   |
|                                  | 19 (66.4)                             | 1 (4.5)                                   | 2 (9.1)                                   | 0                                         |
|                                  | 3 (100)                               |                                            | 0                                         |                                            |
|                                  | 6 (65.5)                              |                                            |                                            | 11 (19.0)                                 |
|                                  | 16 (72.7)                             |                                            |                                            | 4* (18.2)                                 |
|                                  | 2 (66.7)                              |                                            |                                            | 1 (33.3)                                  |
| Multidrug resistance             | 1 (1.7)                               | 0                                         | 0                                         |                                            |
|                                  | 11 (19.0)                             |                                            |                                            | 41 (18.2)                                 |
|                                  | 1 (33.3)                              |                                            |                                            | 1 (33.3)                                  |

Notes:
1) # – P<0.05 (in relation to the initial level of the corresponding group);
2) * – P<0.05 (in relation to the patients with *1/*1 genotype).
At the end of the in-patient treatment the processes of destruction remained in 29.3% of RM and one-third of SM (Table 1). At the same time in IM the processes mentioned above were in 4.5%. Thus, the signs of pulmonary destruction were 6.5 times more in the individuals with *1/*1 genotype than in the individuals with *1/*2 genotype (P<0.05; χ²=5.61). In all groups as the result of the treatment provided there was reduction of the number of patients with the symptoms of destruction, particularly in IM (P<0.05; χ²=11.46) (Table 2). Termination of destruction was observed in 27.3% of the persons with *1/*1 genotype, in two-thirds of *2/*2 genotype carriers and in 90.9% of the individuals with *1/*2 genotype. Thus, conversion of the pulmonary destruction in IM occurred 3.3 times more often (P<0.05; χ²=11.89) than in RM, and it took about 60 days on an average.

At the end, as well as at the beginning of the in-patient treatment, in majority of RM and IM (53.4% and 81.8%, respectively) infiltrative tuberculosis was observed (Fig. 1). Thus, at the end of the treatment provided an infiltrative TB occurred in IM 1.5 times more often than in RM (P<0.05; χ²=5.41). At the same time the two-third of SM had a disseminating form of pulmonary TB.

As a result of the treatment conducted, the number of RM and IM with tuberculosis infiltration decreased by 5.6 times (P<0.05 χ²=31.73) and by 8.1 times (P<0.05; χ²=6.84), respectively; further spreading (contamination) of TB in lungs stopped (P<0.05; χ²=19.92 and χ²=8.32, respectively) (Table 1).

In IM at the end of the in-patient treatment the further spreading (contamination) of TB in lungs was terminated, and the difference was significant in relation to the baseline, as well as in relation to the RM stationary treatment ceased phenomenon of disintegration, and the difference was statistically significant in relation to the baseline (P<0.05; χ²=8.32) and RM (P<0.05; χ²=3.85). At the same time the signs of resorption and con-
Table 2

Conversion of destruction and positive smears depending on CYP2C19 genotype

| Genotype of patients | Conversion of destruction | Conversion of positive smears according to bacterioscopy | Conversion of positive smears according to culture |
|----------------------|--------------------------|--------------------------------------------------------|--------------------------------------------------|
|                      | number of patients (%)   | duration (days) ± SEM | number of patients (%) | duration (days) ± SEM | number of patients (%) | duration (days) ± SEM |
| *1/*1                | 6/22 (27.3)              | 59.7±2.3               | 26/27 (96.3)           | 58.7±1.2             | 13/36 (36.1)           | 69.0±3.3             |
| *1/*2                | 10/11 (90.9)             | 63.7±2.8               | 11/11 (100)            | 57.6±2.1             | 5/13 (38.5)            | 68.6±3.0             |
| *2/*2                | 2/3 (66.7)               | 58.2±5.6               | 2/3 (66.7)             | 47.5±10.1*            | 1/2 (50.0)             | 87                  |

Note: * – P<0.05 (in relation to the patients with *1/*1 genotype).

According to the data of the culture method at the end of the in-patient treatment 40% of the individuals with *1/*1 and *1/*2 genotype, as well as one-third of the individuals with *2/*2 genotype remained smear-positive (Fig. 2). As a result of the treatment, the number of smear-positive patients with *1/*1 genotype decreased by almost 1.5 times (P<0.05; χ²=5.83). The smear conversion observed had almost the same speed in RM and IM – within 69 days (Table 2).

The data obtained have proven that at the beginning of treatment the signs of destruction, infiltration and disintegration were more common in the patients with genotype CYP2C19*1/*1 than in patients with CYP2C19*1/*2 or CYP2C19*2/*2 genotypes. At the end of the in-patient treatment the processes of resorption and abortion of destruction were more often associated with *1/*2 genotype. According to the preliminary data the genotype – *1/*2 mentioned below was associated with a high concentration of isoniazid and a slightly lower concentration of rifampicin in the blood during the treatment [8]. On the other hand, the patients with genotypes *1/*1 or *1/*2 had approximately the same duration of the in-patient treatment and the percentage of positive smears at the beginning and at the end of the treatment provided and the same number of the developed cases of drug-resistant tuberculosis. Unfortunately, it was difficult to assess the impact of the presence of genotype *2/*2 on the tuberculosis process due to the small number of such patients.

CONCLUSIONS

1. At the beginning of the treatment the patients with genotype *1/*1 had manifestations of disintegration and destruction in pulmonary tissues more often than carriers of *1/*2 or *2/*2 genotype.
2. At the end of in-patient treatment the processes of resorption and abortion of destruction were more often associated with *1/*2 than *1/*1 genotype.
3. The patients with *1/*1 or *1/*2 genotypes had approximately the same duration of the in-patient treatment and the percentage of positive smears at the beginning and at the end of the treatment provided and the same number of the developed cases of drug-resistant tuberculosis.

REFERENCES

1. Антоненко П.Б., Кресюн В.Й. // Вісник наукових досліджень. – 2013. – №2. – С. 32-35.
2. Антоненко П.Б., Кресюн В.Й. // Одеський мед. журн. – 2013. – №5. – С. 16-20.
3. Мельник В.М., Новожилова І.О., Матусевич В.Г. та ін. // Укр. пульмонол. журн. – 2012. – №1. – С. 5-7.
4. Наказ МОЗ України №384 від 09.06.2006 р. «Про затвердження протоколу надання медичної допомоги хворим на туберкульоз», Нормативні директивні правові документи. – К., 2006. – 87 с.
НАСЛІДКИ ЛІКУВАННЯ ТУБЕРКУЛЬОЗУ ЛЕГЕНЬ ЗАЛЕЖНО ВІД ГЕНОТИПУ CYP2C19
П.Б.Антоненко, В.Й.Кресюн
Одеський національний медичний університет
Ключові слова: туберкульоз; CYP2C19; наслідки лікування
У попередніх дослідженнях було показано, що поліморфізм гена CYP2C19 у хворих на туберкульоз (ТБ) асоціюєвався з відмінностями у концентраціях рифампіцину та ізоніазида в крові хворих. Метою дослідження було визначення особливостей перебігу та наслідків лікування туберкульозу легень на стаціонарному етапі в залежності від генотипу CYP2C19. Було проведено аналіз медичних карт 83 хворих на вперше діагностований туберкульоз легенів наприкінці стаціонарного лікування у Одеському обласному протитуберкульозному диспансері в 2012 р. з урахуванням генотипу CYP2C19. На початку лікування у хворих, які мали генотип *1/*1, процеси розпаду спостерігався у 3 рази рідше, ніж у хворих з генотипом *1/*2 (10.3% проти 31.8%; P<0.05; χ²=5.40) і в 6.5 разів рідше, ніж у хворих з генотипом *2/*2 (10.3% проти 66.7%; P<0.05; χ²=7.94). Наприкінці стаціонарного лікування ознаки деструкції легеневої тканини спостерігались у 6.5 разів частіше за носіїв генотипу *1/*1, ніж у осіб з генотипом *1/*2 (29.3 versus 4.5; Р<0.05; χ²=5.61). Ознаки розсмоктування і ущільнення легеневої тканини відзначались у 74.1% осіб з генотипом *1/*1, у 95.5% осіб з генотипом *1/*2 і 66.7% осіб з генотипом *2/*2. Достовірна різниця між групами щодо тривалості стаціонарного лікування та розвитку хіміорезистентного туберкульозу була відсутня.

ИСХОД ЛЕЧЕНИЯ ТУБЕРКУЛЕЗА ЛЕГКИХ В ЗАВИСИМОСТИ ОТ ГЕНОТИПА CYP2C19
П.Б.Антоненко, В.И.Кресюн
Одесский национальный медицинский университет
Ключевые слова: туберкулез; CYP2C19; исход лечения
В предыдущих исследованиях было продемонстрировано, что полиморфизм гена CYP2C19 у больных туберкулезом (ТБ) ассоциировался с отличи- ма концентраций рифампицина и изониазида в крови больных. Целью исследования было определение особенностей течения и исходов лечения туберкулеза легких на стационарном этапе в зависимости от генотипа CYP2C19. Был проведен анализ медицинских карт 83 больных с впервые диагностированным туберкулезом легких при завершении стационарного лечения в Одесском областном противотуберкулезном диспансере в 2012 г. с учетом генотипа CYP2C19. В начале лечения у больных, имевших генотип *1/*1, процессы распада наблюдались в 3 раза реже, чем у больных с генотипом *1/*2 (10.3% против 31.8%; P<0.05; χ²=5.40) и в 6.5 раз реже, чем у больных с генотипом *2/*2 (10.3% против 66.7%; P<0.05; χ²=7.94). В конце стационарного лечения признаки деструкции легочной ткани наблюдались в 6.5 раз чаще у носителей генотипа *1/*1, чем у лиц с генотипом *1/*2 (29.3 против 4.5; Р<0.05; χ²=5.61). Признаки рассасывания и уплотнения легочной ткани отмечались у 74.1% пациентов с генотипом *1/*1, у 95.5% лиц с генотипом *1/*2 и 66.7% лиц с генотипом *2/*2. Достоверная разница между группами относительно длительности стационарного лечения и развития химорезистентного туберкулеза отсутствовала.

Address for correspondence: Received in 11.03.2014
2, Valikhovsky lane, Odessa, 65082, Ukraine.
Tel. (48) 717-35-45. E-mail: peterantonenko@yandex.ru.
Odessa National Medical University